Ashkon Software

   







 


CING - Cingulate Inc

Cingulate Inc logo Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

 



 

 

 
Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer